The proceeds will support the execution of the Phase II/III trial and potential NDA submission for the Nectero EAST System, a Breakthrough Therapy for small to medium-sized AAA. TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced the closing of its $96 million Series D financing round. Financing … Continue reading Nectero Medical Announces Completion of $96M Series D Financing